Autoimmunity in MASLD: Focus on autoantibodies, anti-apolipoprotein A1 IgG and G protein-coupled receptors.

IF 4.4 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Sabrina Pagano, Emmanuel Somm, François R Jornayvaz, Nicolas Vuilleumier
{"title":"Autoimmunity in MASLD: Focus on autoantibodies, anti-apolipoprotein A1 IgG and G protein-coupled receptors.","authors":"Sabrina Pagano, Emmanuel Somm, François R Jornayvaz, Nicolas Vuilleumier","doi":"10.1111/eci.70092","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The increasing prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), represents a significant public health concern, as it is closely linked to rising obesity rates and metabolic syndrome, affecting approximately 30% of the global population. In addition, MASLD, along with its more severe form, metabolic dysfunction-associated steatohepatitis (MASH), increases the risk of cardio-metabolic diseases and hepatocellular carcinoma. In recent years, multiple G-protein-coupled receptors (GPCRs) have been identified as potential therapeutic targets for these disorders. Additionally, autoimmunity is believed to potentially play a role in the development of mechanisms contributing to the pathogenesis of MASLD/MASH. This narrative review examines the diverse autoantibodies associated with the disease, with a particular emphasis on antibodies targeting apolipoprotein A-1 (AAA-1) and their relationship with anti-GPCRs antibodies.</p><p><strong>Results: </strong>Several autoantibodies have been identified in up to 30% of individuals with MASLD/MASH, both with and without concomitant autoimmune diseases. Among the anti-GPCR autoantibodies identified in MASLD to date are those targeting the angiotensin II type 1 receptor and the endothelin-1 type A receptor. While the contribution of this class of autoantibodies to MASLD/NASH remains unclear, AAA-1 appears to be pathogenic, acting as pro-steatotic and pro-inflammatory mediators. Additionally, current data suggest shared functional responses between anti-GPCR antibodies and AAA1 in cell-based assays used to detect anti-GPCR presence.</p><p><strong>Conclusion: </strong>A better understanding of the role of humoral autoimmunity and the interactions among its various components in the metabolic dysfunction underlying MASLD/MASH has the potential to open new perspectives for early detection and therapeutic interventions.</p>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":" ","pages":"e70092"},"PeriodicalIF":4.4000,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/eci.70092","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The increasing prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), represents a significant public health concern, as it is closely linked to rising obesity rates and metabolic syndrome, affecting approximately 30% of the global population. In addition, MASLD, along with its more severe form, metabolic dysfunction-associated steatohepatitis (MASH), increases the risk of cardio-metabolic diseases and hepatocellular carcinoma. In recent years, multiple G-protein-coupled receptors (GPCRs) have been identified as potential therapeutic targets for these disorders. Additionally, autoimmunity is believed to potentially play a role in the development of mechanisms contributing to the pathogenesis of MASLD/MASH. This narrative review examines the diverse autoantibodies associated with the disease, with a particular emphasis on antibodies targeting apolipoprotein A-1 (AAA-1) and their relationship with anti-GPCRs antibodies.

Results: Several autoantibodies have been identified in up to 30% of individuals with MASLD/MASH, both with and without concomitant autoimmune diseases. Among the anti-GPCR autoantibodies identified in MASLD to date are those targeting the angiotensin II type 1 receptor and the endothelin-1 type A receptor. While the contribution of this class of autoantibodies to MASLD/NASH remains unclear, AAA-1 appears to be pathogenic, acting as pro-steatotic and pro-inflammatory mediators. Additionally, current data suggest shared functional responses between anti-GPCR antibodies and AAA1 in cell-based assays used to detect anti-GPCR presence.

Conclusion: A better understanding of the role of humoral autoimmunity and the interactions among its various components in the metabolic dysfunction underlying MASLD/MASH has the potential to open new perspectives for early detection and therapeutic interventions.

MASLD的自身免疫:关注自身抗体、抗载脂蛋白A1 IgG和G蛋白偶联受体。
背景:代谢功能障碍相关的脂肪性肝病(MASLD),以前称为非酒精性脂肪性肝病(NAFLD)的患病率日益增加,代表了一个重大的公共卫生问题,因为它与肥胖率上升和代谢综合征密切相关,影响了全球约30%的人口。此外,MASLD及其更严重的形式,代谢功能障碍相关脂肪性肝炎(MASH),增加了心脏代谢疾病和肝细胞癌的风险。近年来,多种g蛋白偶联受体(gpcr)已被确定为这些疾病的潜在治疗靶点。此外,自身免疫被认为可能在MASLD/MASH发病机制的发展中发挥作用。本文综述了与该疾病相关的多种自身抗体,特别强调了针对载脂蛋白a -1 (AAA-1)的抗体及其与抗gpcr抗体的关系。结果:在多达30%的MASLD/MASH患者中发现了几种自身抗体,无论是否伴有自身免疫性疾病。目前在MASLD中发现的抗gpcr自身抗体主要针对血管紧张素II型1受体和内皮素1型A受体。虽然这类自身抗体对MASLD/NASH的作用尚不清楚,但AAA-1似乎是致病的,作为促脂肪变性和促炎症介质。此外,目前的数据表明,在用于检测抗gpcr存在的基于细胞的试验中,抗gpcr抗体和AAA1之间具有相同的功能反应。结论:更好地了解体液自身免疫在MASLD/MASH代谢功能障碍中的作用及其各组分之间的相互作用,有可能为早期发现和治疗干预开辟新的视角。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
9.50
自引率
3.60%
发文量
192
审稿时长
1 months
期刊介绍: EJCI considers any original contribution from the most sophisticated basic molecular sciences to applied clinical and translational research and evidence-based medicine across a broad range of subspecialties. The EJCI publishes reports of high-quality research that pertain to the genetic, molecular, cellular, or physiological basis of human biology and disease, as well as research that addresses prevalence, diagnosis, course, treatment, and prevention of disease. We are primarily interested in studies directly pertinent to humans, but submission of robust in vitro and animal work is also encouraged. Interdisciplinary work and research using innovative methods and combinations of laboratory, clinical, and epidemiological methodologies and techniques is of great interest to the journal. Several categories of manuscripts (for detailed description see below) are considered: editorials, original articles (also including randomized clinical trials, systematic reviews and meta-analyses), reviews (narrative reviews), opinion articles (including debates, perspectives and commentaries); and letters to the Editor.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信